Sorrento Therapeutics Inc. (SRNE): Price and Financial Metrics


Sorrento Therapeutics Inc. (SRNE): $6.35

-0.23 (-3.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

SRNE POWR Grades


  • SRNE scores best on the Growth dimension, with a Growth rank ahead of 84.6% of US stocks.
  • The strongest trend for SRNE is in Quality, which has been heading down over the past 206 days.
  • SRNE ranks lowest in Momentum; there it ranks in the 7th percentile.

SRNE Stock Summary

  • With a price/sales ratio of 39.13, Sorrento Therapeutics Inc has a higher such ratio than 94.09% of stocks in our set.
  • With a year-over-year growth in debt of -39.31%, Sorrento Therapeutics Inc's debt growth rate surpasses only 11.43% of about US stocks.
  • As for revenue growth, note that SRNE's revenue has grown 40.93% over the past 12 months; that beats the revenue growth of 86.93% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Sorrento Therapeutics Inc, a group of peers worth examining would be SSTI, ELF, AMPH, TECH, and OMCL.
  • SRNE's SEC filings can be seen here. And to visit Sorrento Therapeutics Inc's official web site, go to www.sorrentotherapeutics.com.

SRNE Price Target

For more insight on analysts targets of SRNE, see our SRNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.50 Average Broker Recommendation 1.5 (Moderate Buy)

SRNE Stock Price Chart Interactive Chart >

Price chart for SRNE

SRNE Price/Volume Stats

Current price $6.35 52-week high $19.39
Prev. close $6.58 52-week low $2.56
Day low $6.14 Volume 8,361,000
Day high $6.85 Avg. volume 13,894,576
50-day MA $8.24 Dividend yield N/A
200-day MA $9.14 Market Cap 1.82B

Sorrento Therapeutics Inc. (SRNE) Company Bio


Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.


SRNE Latest News Stream


Event/Time News Detail
Loading, please wait...

SRNE Latest Social Stream


Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chance

OGCN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators.

Chris Lau on InvestorPlace | May 7, 2021

Sorrento: The Monoclonal Antibody Portfolio Charges Ahead

The developments are coming in thick and fast at Sorrento Therapeutics (SRNE). Recent times have seen a flurry of announcements regrading the company’s bulging pipeline. Earlier this week, the company gave an update on the progress being made with several fully human monoclonal antibodies (mAbs) intended to treat COVID-19 and different types of cancers. The treatments are based on the company’s G-MAB technology platform, which H.C. Wainwright’s Ram Selvaraju says is “bearing fruit at a prodigious rate.” “This demonstrates the potential of the deep pipeline generated from Sorrento’s proprietary G-MAB™ library,” the 5-star analyst said in reference to the update.

Marty Shtrubel on TipRanks | April 30, 2021

Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE ) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI-3031 is based on Sorrento's G-MAB library that has fostered the development of several oncology programs currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently … Full story available on Benzinga.com

Benzinga | April 27, 2021

Why Sorrento Therapeutics' Stock Is Trading Higher Today

Sorrento Therapeutics (NASDAQ: SRNE ) shares are trading higher … Full story available on Benzinga.com

Benzinga | April 27, 2021

Why Sorrento Therapeutics Stock Is Soaring Today

The biopharmaceutical company did not report any news, but perhaps the market is responding to comments made by Mad Money host Jim Cramer regarding Sorrento Therapeutics on his show on Friday, April 23. Jim Cramer's comments hardly painted a bullish picture of Sorrento Therapeutics. During the lightning round bell -- when he gives quick and short answers to callers' questions on various stocks -- Cramer said the following: "There'll be a news release and it'll spike 3-4 points ... and that'll give you a chance to get out."

Yahoo | April 26, 2021

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo -14.01%
3-mo -55.87%
6-mo -1.55%
1-year 142.37%
3-year -13.01%
5-year 11.01%
YTD -6.96%
2020 101.92%
2019 40.83%
2018 -36.84%
2017 -22.45%
2016 -43.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9328 seconds.